Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Wondering if Recursion Pharmaceuticals at around $4.83 is a beaten down bargain or a value trap? This breakdown walks through what the current market price is really implying. The stock has bounced ...

Dec 8 (Reuters) - Recursion Pharma, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths in the colon in ...

The native just-in-time compiler in Python 3.15 can speed up code by as much as 20% or more, although it’s still experimental ...

2025 has come and gone. It was an interesting year and had its fair share of weird Vancouver stories. We’ve gone through some ...

AI can help design AI systems: automating architecture choices, discovering algorithms, and optimizing hardware ...

In particular, the rally after Gary Gensler’s ousting suggests that the blockchain ecosystem’s value is underpinned by how ...

Toward the end of this decade, a choice may face the species that could reshape its interactions with intelligence itself and ...

Shanda Group has entered a period of renewed visibility, with a series of incubated ventures coming to light over the past ...

Broadcom enters 2026 at an inflection point, with strong tailwinds from its ASIC and Networking segments. Read why AVGO stock ...

The surge of AI has, for an array of users, complicated tasks such as fixing a blocked bank account, reporting fraud or ...